Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

If cord blood stem cells are the future, why aren't we saving them?

15 June 2006

By Dr Karen Devine

Kent Law School, University of Kent

Appeared in BioNews 363
This week saw the long awaited report from the Royal College of Obstetricians and Gynaecologists (RCOG), which stated its latest position on the public and private banking of umbilical cord blood stem cells. Essentially, their stance remains unchanged from the one taken in their previous opinion paper published in 2001. The RCOG stands firm in its decision not to support commercial storage where no history of medical illness exists, but continues to back both public donation to banks such as the NHS Cord Blood Bank for non-directed use and directed donations for at-risk families. There are, however, currently only two active public banks in the UK. Given the medical advancements that have been made within the stem cell field over the past 20 years, the time has now come for the NHS to consider an improved funding infrastructure to secure access to all, says the RCOG.

Stem cells from umbilical cord blood (UCB) have been used since the first successful transplant in 1988 on Matthew Farrow, a five- year-old boy who suffered from Fanconi's Anaemia. Medical experts carried out the procedure at a hospital in Paris using the stem cells harvested from the cord blood of his newborn sister, Alison. This was to become the first of over 6,000 UCB transplants worldwide, treating disorders such as thalassaemia, immunodeficiency, inherited metabolic diseases, aplastic anaemia and acute leukaemia. Today, Matthew remains durably grafted and living proof that UCB has enormous future potential.

Cord blood advocates are keen to point out the benefits of using UCB for transplant purposes as an alternative to the traditional method of bone marrow. Unlike its bone marrow counterpart, UCB stem cells need not be an exact match and are less likely to be rejected by the recipient. Cord blood is a readily available resource, collected at the moment of delivery without pain or relative risk to mother and baby. Furthermore, stem cells collected from this routinely discarded waste product fail to raise the same moral, social and religious objections associated with the procurement of stem cells from aborted foetuses and embryos created via assisted reproductive technology. So, what reasons are being given for ignoring a resource with such great potential?

Within the public sector, the logistics of collection from multiple hospitals and subsequent cost implications involved in collection and storage are obvious reasons given against routine collection, which would inevitably draw heavily on an already cash-starved NHS. With regard to the private sector, many legal and ethical issues are raised. In spite of its potential, the RCOG purport that there remains insufficient evidence to recommend UCB collection in low-risk families. Expectant families are targeted by the use of emotive advertising literature in maternity clinics and the Internet. Critics of commercial banking argue that the costs of this service, which fall in the region of £1,200 for a 15-20 year storage term, are out of proportion in terms of the odds associated with their potential future use, currently estimated at between 1 in 20,000 and 1 in 2,700 for personal use. Furthermore, personal banking may not be deemed necessary for certain conditions as alternative resources may be available from UK and international public cord blood banks and bone marrow registries. Critics also argue that personally banked UCB may contain disorders already present in the patient at birth, but as yet undetected, and the low number of cells within a unit means they may only be used at present for transplants in children and young adults. Concerns over storage conditions and longevity of the cells are also raised.

NHS Trusts within the UK have been advised by the RCOG and the Royal College of Midwives that they do not support this practice for non-indicated patients, and that each Trust should develop its own policy on how to respond to such requests from patients. It is feared that Trusts may be subject to liability claims where the collected unit is insufficient in quantity, contaminated or mislabelled and staff may be exposed to needle-stick injury. Furthermore, the collection process, which takes place in the third stage of labour, may compromise the needs of mother and baby post-partum and other patients within the labour ward. To this end, the NHS Litigation Authority has advised that they will not provide an indemnity under the Clinical Negligence Schemes for Trusts if staff undertake this procedure.

Although opinion remains divided over the need for parents to privately bank their baby's cord blood, those on either side of the debate agree on one thing - stem cells are the future - and, in particular, UCB stem cells show great promise. Until such time as the Government fully responds to the RCOG's calls for the sufficient funding and expansion of public banks, private companies can hardly be criticised for providing a service where an alternative fails to exist.

SOURCES & REFERENCES

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

15 June 2009 - by Heidi Colleran 
Ireland is being 'left way behind' in providing future sources of stem cells harvested from the umbilical cord blood of newborns, because of insurance-related policies preventing their collection. Professor Colin McGuckin, president of Novus Sanguis, an international research consortium on cord blood and stem cell research has called on Irish parents to sue the Irish Health Service Executive (HSE) when denied the service....
20 April 2009 - by Dr Rebecca Robey 
Canadian scientists have found a new way to prompt haematopoietic stem cells (HSCs) from the bone marrow of mice to multiply, in order to provide a large quantity of HSCs from a small sample of bone marrow. They hope that this technique, if it also works in...
07 July 2008 - by Dr Karen Devine 
This week saw the introduction of licensing agreements for UK premises that wish to undertake the collection of umbilical cord blood (UCB) stem cells on behalf of pregnant women. Cord blood has been collected and used in the treatment of certain blood diseases such as leukaemia, and...
06 May 2008 - by Dr Karen Devine 
The UK's Human Tissue Authority (HTA) has announced that the collection of umbilical cord blood stem cells is to be regulated for the first time in the UK. Cord blood contains a rich source of stem cells that could be used to fight disease and may in...
06 May 2008 - by Dr Karen Devine 
In the 21st Century, the collection and use of stem cells from umbilical cord blood (UCB) is anything but a new phenomenon. Since the first successful UCB transplant in 1988, the use of UCB for transplantation purposes has been used in over 6,000 treatments worldwide and has proved to be...

18 June 2006 - by Heidi Nicholl 
The Royal College of Obstetricians and Gynaecologists (RCOG) has issued an updated version of its Scientific Opinion Paper on Umbilical Cord Blood Banking. The report finds that there is little evidence to recommend the practice whereby private companies collect and store umbilical cord blood for up to...
31 August 2005 - by BioNews 
A couple living in County Londonderry have spoken to the press about their decision to collect stem cells from their newborn baby's umbilical cord. The cells are to be stored for possible use later in his life, to help treat a number of diseases or conditions he might develop. The...
22 August 2005 - by BioNews 
Scientists have discovered adult stem cells in umbilical cord blood that may have the same properties as embryonic stem (ES) cells. Dubbed 'cord-blood-derived embryonic-like stem cells' (CBEs), these cells might have a potential similar to ES cells, offering the possibility of a less controversial way to repair tissue damage from...
26 November 2001 - by BioNews 
The Royal College of Obstetricians and Gynaecologists (RCOG) warned parents in the UK last week against banking the cord blood and umbilical cells from their babies in order to have 'insurance' against future diseases in their children. Scientists and doctors have said that the procedure cannot be justified on scientific...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation